Hibiki Kawamata is an Assistant Professor of Research at the Brain and Mind Research Institute within Weill Cornell Medical College , where they have contributed to neuroscience research since 2015. Ph.D. from Weill Cornell Graduate School of Medical Sciences (2008) B.A. from Smith College (1999) Dr. Kawamata's research focuses on mitochondrial dysfunction , protein misfolding , and their roles in neurodegenerative diseases such as ALS and Parkinson's. Their work explores oxidative stress , calcium homeostasis , and metabolic pathways in disease progression. Key publication trends include studies on mitochondrial dynamics , neurodegenerative biomarkers , and genetic modifiers in ALS models. Recent work (2025) examines CHCHD10/CHCHD2 amyloid structures, while earlier studies (2020-2011) investigate metabolic profiling , ER-mitochondria interactions , and proteinopathy mechanisms . Dr. Kawamata's grants include NINDS funding for CHCHD10/ALS research (2024-2029) and support from the Muscular Dystrophy Association (2022-2025). They have published extensively on mitochondrial biology in neurodegeneration, with >150 citations for their 2018 work on ALS-FTLD protein interactions .
Mingrui Zhao is an Associate Professor of Research in Neuroscience at the Brain and Mind Research Institute , Weill Cornell Medical College , with a focus on neurovascular coupling, epilepsy, and neurodegenerative diseases. Their work integrates advanced imaging techniques and genetic models to study seizure mechanisms and tau pathology. Education : M.S. from Beijing University of Chinese Medicine (1996), Ph.D. from Chinese Academy of Medical Sciences (1999), B.M. from Hebei Medical University (1993) Research Interests include neurovascular coupling dynamics during seizures, optogenetic tools for epilepsy network analysis, and molecular pathways in tauopathy. Their studies use animal models and human iPSC-based systems to uncover therapeutic targets. Recent Articles highlight work on APOE3 mutations in tau resilience, laser-based seizure control, and neurovascular uncoupling mechanisms. Publications span journals like Immunity , Cell , and Nature Neuroscience . Primary Email : miz2003@med.cornell.edu
Prof. Dr. med. Ruxandra Bachmann-Gagescu is an Associate Professor in Developmental Genetics at the University of Zurich , leading a research group within the Department of Molecular Life Sciences and the URPP Adaptive Neural Circuits (AdaBD) . Her work bridges human genetics , zebrafish models , and iPSC-based cellular systems to unravel the molecular basis of monogenic developmental diseases affecting the brain, kidney, and retina . Current focus: Ciliopathies (e.g., Joubert Syndrome) and their multisystem manifestations Clinical practice: Genetic diagnosis/counseling for inherited retinal/renal diseases Research Highlights: Her group investigates primary cilia —cellular antennae regulating signaling and homeostasis—through: Zebrafish mutants modeling CNS and retinal defects iPSC-derived 2D/3D models to study neuronal/kidney pathomechanisms Proteomic approaches to define cell-type-specific ciliary composition The lab contributes to large-scale initiatives like the European PREDICT Consortium (genetic modifiers in ciliopathies) and PRAECLARE (variant interpretation assays). Scientific Awards: SNSF Ambizione Fellowship (2012): Established her research niche in ciliopathies SNSF Professorship Grant (2017): Enabled independent lab leadership Advising & Collaborations: Mentors PhD and Master’s students in cilia biology and translational genetics. Collaborates with international experts in retinal disease (Sophie Saunier, Paris), kidney disorders (Carsten Wagner, Zurich), and bioinformatics (Pedro Beltrao, ETH Zurich). Labs & Teams: Based at the University of Zurich Irchel Campus (Y13-K-48/Y13-K-03), her team includes postdocs (Markus Masek), PhD students (Ellen Aarts, Arianna Cuoco), and lab manager Claudia Hofmann . Projects span zebrafish genetics , human iPSC differentiation , and clinical-genetic correlations .
Prof. Olivier Devuyst is a Full Professor and Head of the 'Mechanisms of inherited kidney disorders' research group at the Department of Physiology, University of Zurich. He co-leads the University Research Priority Program (URPP) ITINERARE (2021-2032), a translational initiative targeting rare diseases affecting 500,000 people in Switzerland. His work integrates molecular genetics, patient studies, and animal models to investigate renal fluid/electrolyte homeostasis and its clinical implications for hypertension, kidney stones, and dialysis. His primary research interests focus on epithelial transport mechanisms in kidney tubules, with emphasis on water/ion channels, lysosomal storage disorders, and genetic mutations underlying tubulopathies and polycystic kidney disease. Key projects include: TRPV4 mechanosensing in proteinuria, uromodulin's role in hypertension and urinary tract infection resistance, and AQP1 regulation in peritoneal dialysis. His group pioneers translational approaches linking rare disease insights to common conditions like progressive renal failure. Recent publications (2019-2023) reveal strong trends in lysosomal-autophagy pathways and genetic modifiers of renal function , with high-impact studies in Nature Communications, NEJM, and Science Signaling demonstrating how rare disease mechanisms inform treatments for dialysis patients and genetic hypertension. His scientific awards include: 2019 Award for Outstanding Basic Science Contributions to Nephrology (ERA-EDTA) 2019 Dr. D.G. Oreopoulos Memorial Award (Canadian Society of Nephrology) Devuyst actively advises PhD students through UZH's Life Science Graduate School and secures major grants via: EU consortia : TrainCKDis, EUNEFRON, EURenOmics, TranCYST Swiss networks : NCCR Kidney.CH, ERA-EDTA Working Group on Inherited Kidney Disorders The MIKADO lab maintains extensive biobanks including 500+ kidney biopsies and 800+ peritoneal dialysis DNA samples, utilizing transgenic mouse models, segment-specific cell cultures, and high-throughput genomic platforms to dissect tubular transport defects and develop targeted therapies.
John Denu is a Professor at the University of Wisconsin–Madison leading the Denu Laboratory, which is part of the Microbiome, Epigenetics, and Multi-omics hubs at the Wisconsin Institute for Discovery. His research program investigates the molecular connections between metabolism and epigenetic pathways in human health and age-associated diseases. The lab employs biochemical, genetic, and multi-omics approaches to study chromatin dynamics, utilizing mammalian tissue culture systems and mouse models. Denu's research interests center on understanding how metabolic pathways influence epigenetic regulation. His work focuses on three primary areas: the molecular links between metabolism and epigenetic pathways; the biochemical principles governing epigenetic information written onto histones; and the role of sirtuins in reversible protein acetylation. His lab explores how chromatin remodeling enzymes rely on metabolite-derived co-enzymes, suggesting coordination between nuclear events and metabolic networks. He investigates the hypothesis that chromatin modifying complexes have evolved to sense metabolite levels and respond accordingly. Analysis of his recent publications reveals a strong focus on metabolism-epigenome interactions, with particular emphasis on sirtuins, histone modifications, and the role of specific metabolites like citrate and short-chain fatty acids in regulating chromatin function. His work spans from fundamental biochemical mechanisms to disease-relevant models, particularly in neurodegeneration and aging. Denu mentors several graduate students including Jessica Han (who recently defended her PhD on diet, gut microbiome, and metabolism converging to remodel epigenetics) and Kellen Biesbrock (who joined in 2025). His lab actively collaborates with researchers across campus, including with Prof. Federico E. Rey in the Department of Bacteriology. The Denu Laboratory employs an interdisciplinary approach spanning basic biochemistry to big data, using methods ranging from in vitro enzyme assays to high-throughput mass spectrometry. The lab is actively involved in many collaborations both on and off campus, reflecting the integrative nature of metabolism-epigenome research.
Sten Stemme is a Tutor at the Department of Oncology-Pathology, Karolinska Institutet (2024–2026). His research spans cancer biology, immunology, and cardiovascular diseases. Education: Docent (1995) Sten Stemme's research focuses on cancer and oncology , particularly tumor pathology (uterine sarcomas, endometrial stromal tumors, colorectal polyps) and immune interactions in atherosclerosis. His work explores cytokine signaling, scavenger receptors (e.g., CXCL16/SR-PSOX), and T-cell responses to oxidized lipids. His publications (1995–2015) include studies on atherosclerosis (T-cell infiltration, scavenger receptors, interferon-γ effects), cancer prognosis (mitotic index, hormone receptors), and diagnostic methodologies (RT-PCR, flow cytometry).
Dr Francisco Rivero Crespo is Reader in Molecular Cell Biology at Hull York Medical School , University of Hull. He serves as Postgraduate Training Scheme Lead and is a Fellow of the Higher Education Academy (FHEA), contributing extensively to MB BS Medicine, MSc Pharmacology and Drug Development, and Department of Biomedical Sciences teaching programmes. Education MD, University of Valladolid (1989) PhD, Institute of Biochemistry, CSIC-Universidad Complutense, Madrid (1994) Postdoctoral fellowships: Max-Planck Institute for Biochemistry, Martinsried (1994-1997) and University of Cologne (1997-1998) Research Interests Dr Rivero’s laboratory investigates the cytoskeleton , focusing on actin dynamics and signalling pathways regulating cytoskeletal remodelling in blood platelets. His work explores how platelet activation—mediated by intricate signalling cascades—drives morphological changes required for adhesion, spreading, and aggregation at sites of vascular injury. A translational dimension of his research aims to improve diagnostics and therapeutics for thrombotic disorders underlying cardiovascular conditions such as heart attack and stroke. Publications Overview Across more than 50 peer-reviewed papers, Dr Rivero has advanced understanding of platelet physiology , actin-binding proteins , and signalling scaffolds . Recent outputs highlight roles for coronins, RhoBTB3, plastin-1 and cyclase dynamics in platelet and sensory cell biology, bridging in vitro biochemical assays to in vivo mouse models. Scientific Awards & Recognition Fellow of the Higher Education Academy (FHEA) Editorial board member: Scientific Reports , Cells , and BMC Molecular and Cell Biology Supervision & Funding Dr Rivero presently supervises Paulo Saldanha (PhD) and has mentored David Riley, Anisha Chacko, Jawad S. Khalil, Pooja Joshi and Julia Lutz to PhD completion. He welcomes new postgraduate researchers interested in cytoskeletal biology, platelet signalling, and translational cardiovascular research. Laboratory & Collaborations The lab is embedded within the Hull York Medical School research environment, fostering collaborations with clinicians and basic scientists across the UK and Europe. Facilities include advanced live-cell imaging, flow-based adhesion assays, and genetically modified mouse colonies, enabling multifaceted investigation of cytoskeletal dynamics in health and disease.
Daylon J James, PhD is an Associate Professor at Weill Cornell Medical College, holding concurrent appointments since 2022 in Obstetrics and Gynecology , Genetic Medicine , and Reproductive Medicine . His laboratory integrates stem-cell biology, vascular engineering, and reproductive endocrinology to address fundamental questions in ovarian biology and fertility preservation. Education Ph.D., The Rockefeller University (2006) B.S., Duke University (1999) Research Focus Dr James’s research centers on three interlocking themes: (1) deriving and manipulating human pluripotent stem cells to create vascular networks and specialized endothelial subtypes, (2) deciphering the molecular cues that govern ovarian follicle development, aging, and depletion, and (3) translating these insights into strategies that protect or restore ovarian reserve in patients facing gonadotoxic therapies. His work exploits biomaterial platforms, xenograft models, and single-cell ‘omics’ to bridge bench discoveries with clinical fertility preservation. Publication Trends Across more than 50 peer-reviewed papers since 2005, two dominant arcs emerge: early foundational studies on endothelial differentiation and vascular niche engineering, followed by a translational pivot toward ovarian biology, AMH-based therapeutics, and chemotherapy-induced ovarian damage. Recent high-impact contributions (2022-2025) emphasize AMH modulation, IGF-1 signaling, and lipid-mediated regulation of genomic stability in both ESCs and human ovarian tissue. Funding & Grants NICHD R01 “Anti-Mullerian hormone for preserving ovarian function …” (Principal Investigator, 2023-2028) NICHD Co-Investigator Award (2021-2024) Laboratory & Affiliations Dr James directs active research programs within the Ansary Stem Cell Institute and the Institute for Reproductive Medicine at Weill Cornell. His group maintains collaborative pipelines with clinical IVF units, enabling rapid translation of engineered endothelial co-transplantation strategies and modified-RNA therapeutics into first-in-human ovarian tissue graft trials.
Li Gan, Ph.D., is the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases at the Brain and Mind Research Institute, Weill Cornell Medical College. Since 2018 she has led an interdisciplinary program that integrates human iPSC-based disease modeling, single-cell multi-omics, and therapeutic target discovery to combat Alzheimer’s disease and related tauopathies. Education Ph.D., Yale University School of Medicine (1996) B.S., Peking University, China (1990) Research Focus Dr. Gan’s laboratory investigates how microglial innate immunity, tau post-translational modifications, and sex-specific pathways drive neurodegeneration. Using CRISPR-engineered human induced pluripotent stem cell (iPSC) models, brain organoids, and chimeric mouse brains, her team decodes cell-type-specific vulnerabilities and designs first-in-class therapeutics—including cGAS inhibitors, anti-acetyl-tau antibodies, and small-molecule modulators of microglial homeostasis. Grants & Support NIA “Mapping proteomic changes of tauopathy in human neurons” (PI, 2025-2030) Cure Alzheimer’s Fund “Sex-biased TLR7 signaling” (PI, 2025) NIA “Acetylated Tau Immunotherapy” (PI Subaward, 2025-2026) JPB Foundation “Targeting maladaptive innate immune response” (PI, 2024-2027) Rainwater Charitable Foundation series on cGAS inhibitors and 4R tauopathy models (PI, 2024-2025) Chan Zuckerberg Initiative & Ludwig Family Foundation awards for neuro-immune resilience studies Industry & Advisory Roles Dr. Gan serves as Scientific Advisory Board Member for Arvinas, Inc. and Neurovanda Therapeutics; consultant to Aeton Therapeutics, LSG Therapeutics, and NeuroLambda Therapeutics; and maintains equity/proprietary interests in these companies plus Retro Biosciences, reflecting long-standing translational collaborations. Laboratory & Teams The Gan Lab operates within the Brain and Mind Research Institute’s state-of-the-art facilities, hosting post-doctoral fellows, graduate students, and research technicians focused on high-throughput CRISPRi/a screening, single-cell epigenomics, and pre-clinical testing of therapeutic leads. Active partnerships extend to the NIH-funded Alzheimer’s Disease Tau Platform Clinical Trial Network and international open-science consortia.
Zhaolan Zhou is a Professor of Genetics at the University of Pennsylvania School of Medicine and a Core Member of the Epigenetics Institute. His research focuses on understanding the epigenetic mechanisms underlying brain development and neurological disorders. Education: B.S. in Bioengineering from Nankai University (1991) M.S. in Genetics from Chinese Academy of Sciences (1994) Ph.D. in Molecular and Cellular Biology from Harvard University (2001) He completed postgraduate training as a Helen Hay Whitney Postdoctoral Fellow at Harvard Medical School and Children's Hospital Boston (2003-2008) and as an S.O. Mast Fellow at the Marine Biological Laboratory in Woods Hole (2002). Research Interests: Dr. Zhou's laboratory investigates the epigenetic control of genome function in brain development and disease, with particular focus on neurogenetics and neuroepigenetics. His team explores how DNA methylation, histone modification, and genomic editing mechanisms contribute to neurodevelopmental and neuropsychiatric disorders including Rett syndrome, CDKL5 deficiency disorder, autism spectrum disorder, and major depressive disorder. The lab employs cutting-edge genomic technologies, cellular and physiological assays, and genetically modified mouse and human induced pluripotent stem cell models to uncover pathophysiological mechanisms and develop therapeutic interventions. Three major research themes guide the Zhou laboratory: (1) Understanding the molecular basis of stress vulnerability and its relationship to major depressive disorder; (2) Gaining pathogenic insights into X-linked disorders like Rett syndrome and CDKL5 deficiency disorder by overcoming challenges posed by X chromosome inactivation; and (3) Investigating how epigenetic regulation controls synaptic gene expression in the brain, particularly how DNA methylation interacts with histone modifications in the context of autism spectrum disorders. Research Trends: Dr. Zhou's recent publications demonstrate a consistent focus on epigenetic mechanisms in neurodevelopmental disorders, particularly X-linked conditions. His work increasingly integrates advanced genomic technologies with sophisticated animal models to dissect disease mechanisms at cellular and circuit levels. There's a clear progression toward developing therapeutic strategies, with several recent papers exploring the reversibility of symptoms in disorder models. His research bridges basic molecular mechanisms with translational applications, as evidenced by studies identifying potential biomarkers and treatment-responsive endpoints for conditions like Rett syndrome. Scientific Contributions: Development of innovative models to overcome X-linked cellular mosaicism in studying disorders like Rett syndrome Pioneering work on the role of epigenetic regulation in stress vulnerability and depression Advancing understanding of how DNA methylation and histone modifications collaboratively regulate synaptic gene expression Developing CRISPR-based epigenomic editing approaches for locus-specific manipulation Training and Mentorship: Dr. Zhou has mentored numerous graduate students, postdoctoral fellows, and research specialists who have gone on to successful careers in academia, industry, and medicine. His lab currently includes postdoctoral fellows, PhD students from multiple graduate groups, research specialists, and undergraduate researchers. His former trainees have secured positions at prestigious institutions including Yale University, Stanford University, and the Children's Hospital of Philadelphia, with several receiving competitive fellowships and awards during their training. Research Environment: The Zhou laboratory is situated within the Department of Genetics at the University of Pennsylvania School of Medicine, with strong connections to the Epigenetics Institute and multiple graduate groups. The lab employs a multidisciplinary approach, combining "omics" technologies, epigenetic remodeling using adapted CRISPR systems, mouse phenotyping, confocal microscopy, electrophysiology, and biochemical characterization to address complex questions in neuroepigenetics.
Angela Gritti is an Associate Professor of Human Histology at Vita-Salute San Raffaele University and a Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) since 2006. Her work focuses on genetic neurodegenerative diseases , particularly Leukodystrophies and GM2 gangliosidosis , using neural stem cells and gene therapy approaches. PhD in Basic Sciences and Veterinary Biotechnology (University of Turin, 2006) Specialty in Toxicology (University of Milan, 1996) Degree in Biological Sciences (University of Milan, 1990) Her research explores regenerative medicine and gene therapy through neural stem cell biology , focusing on: Pathogenesis of lysosomal storage disorders iPSC modeling of human CNS diseases AAV/lentiviral vector safety Epigenetic modulation of oligodendrocytes Preclinical development for metabolic CNS diseases The articles section reveals her contributions to gene therapy safety , iPSC neural modeling , and combined cell/gene strategies for leukodystrophies. Despite extensive grant reviewer roles (ERC, AFM Telethon, EJPRD) and international collaborations with institutions in France, Norway, and the USA, no formal scientific awards are listed in the current text. She has supervised 12 PhD students and 22 master's students while leading funded projects with institutions like the Bespoke Gene Therapy Consortium (NIH), European Leukodystrophy Association , and Italian Telethon Foundation . Her lab also contributes to patient advocacy through educational outreach and clinical translation frameworks.
Suming Huang serves as Professor and Chair of the Four Diamonds Epigenetics and Gene Regulation Research Program in Pediatric Oncology at Penn State University's College of Medicine. Holding dual appointments in the Department of Pediatrics Division of Hematology and Oncology and the Department of Molecular and Precision Medicine, Huang directs research within the Penn State Cancer Institute's Mechanisms of Carcinogenesis program. With an h-index of 36 and over 4,000 citations, Huang maintains an active research profile through the National Cancer Institute. Huang's research centers on epigenetic mechanisms in leukemia development, specializing in transcriptional regulation, non-coding RNA functions, and chromatin organization. Key focus areas include TAL1/SCL regulation in T-cell leukemia, lncRNA-mediated genome organization in AML, and the role of histone modifiers like HDAC1 in tumor suppression. The research integrates hematopoietic stem cell biology with leukemogenesis pathways, particularly examining how non-coding RNAs reprogram chromatin architecture in NUP98-rearranged leukemias and other hematological malignancies. Current publication trends reveal consistent output in high-impact oncology journals, with 2025 publications examining CK2α deletion effects on stem cells, IKAROS/HDAC1 heterochromatin regulation, guanine biosynthesis blockade in MLL leukemias, and HoxBlinc lncRNA functions. These works demonstrate Huang's shift toward therapeutic targeting of epigenetic vulnerabilities while maintaining core investigations into transcriptional dysregulation in pediatric cancers. Huang leads eight major research projects including the active National Cancer Institute grant Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization (2021-2025). Past projects span leukemogenesis mechanisms, long non-coding RNA functions in hematopoiesis, and TAL1 regulation in T-cell leukemia, securing sustained NCI funding since 2008. The research program maintains strong collaborations across hematology-oncology and molecular medicine departments. The Four Diamonds Epigenetics and Gene Regulation Research Program in Pediatric Oncology serves as Huang's primary research hub, focusing on translating epigenetic discoveries into therapeutic strategies for childhood leukemias. Current work integrates multi-omics approaches to dissect lncRNA-mediated chromatin reorganization in leukemic stem cells.
Edward Hawrot is the Alva O. Way Professor of Molecular Biology, Cell Biology and Biochemistry at Brown University's Division of Biology and Medicine. He has been at Brown since 1990, initially serving as Chair of the Section of Molecular Pharmacology. His research focuses on nicotinic acetylcholine receptors and the neurotoxins that target them, with particular emphasis on structure-function relationships. Hawrot received his Ph.D. in Biochemistry from Harvard University and completed postdoctoral training at Harvard Medical School as a Helen Hay Whitney Postdoctoral Fellow working with Paul Patterson. Prior to joining Brown, he spent ten years on the faculty in the Department of Pharmacology at Yale University School of Medicine. His research spans multiple areas including molecular pharmacology, drug design and discovery, nicotine receptor biology, proteomics, and transgenic mouse models. Hawrot's laboratory pioneered the development of a knock-in mouse model where the alpha3 gene was modified to impart sensitivity to alpha-bungarotoxin, enabling systematic determination of alpha3-containing nAChR roles in behavior and nervous system function. His work combines biochemical, biophysical, and molecular biological approaches to understand drug-receptor interactions at the molecular level. Hawrot has received significant funding from NIH and NSF, including grants for mass spectrometry equipment, training programs, and research on nicotinic receptors in pulmonary hypertension. His publication record spans over 70 articles with consistent output through 2021, demonstrating sustained research productivity in receptor biology and neuropharmacology. Established Investigator of the American Heart Association Upjohn Professor of Pharmacology Fellow of the American Association for the Advancement of Science (2011) Multiple NIH study section appointments (2005-2015) Hawrot has served on multiple NIH study sections and has been an active member of several professional organizations including the American Society for Pharmacology & Experimental Therapeutics, American Society for Biochemistry and Molecular Biology, and Society for Neuroscience. His laboratory has developed innovative techniques including the 'pharmatope' approach for engineering receptor sensitivity to alpha-bungarotoxin, creating valuable tools for neuroscience research.
Christopher J. Percival is an Associate Professor in the Department of Anthropology at Stony Brook University. He obtained his Ph.D. from Pennsylvania State University in 2013 and specializes in the genetic and developmental basis of craniofacial variation using mouse models. Education: Ph.D. in Anthropology, Pennsylvania State University (2013) Research Interests focus on: Quantifying genetic contributions to skull morphology Developmental biology of craniofacial structures Evolutionary implications of morphological variation Establishing genotype-phenotype associations in mouse models Key Research Approaches: 3D morphometric landmark analysis Diallel genetic studies Mouse Collaborative Cross project Allometric correction techniques Notable Collaborations: University of Calgary, University of Colorado School of Medicine, UCSF School of Medicine, University of North Carolina-Chapel Hill Technical Expertise: Micro-computed tomography (μCT), Procrustes superimposition, MorphoJ software, BayesDiallel modeling
Thomas Kitzler is a Scientist at the Montreal University Health Centre (IR-MUHC) and an Assistant Professor in the Department of Human Genetics at McGill University . His research focuses on genetic and genomic mechanisms of kidney diseases , particularly congenital anomalies of the kidney and urinary tract (CAKUT) , focal segmental glomerulosclerosis , and renal ciliopathies . Affiliations : Center for Translational Biology Child Health and Human Development Program Division of Genetics, MUHC His laboratory utilizes whole-exome sequencing , zebrafish models , and patient-derived cell systems to uncover novel disease genes and pathways. Recent publications highlight discoveries in COL4A1 , ZMYM2 , and C2CD3 mutations linked to renal and neurodevelopmental disorders. Dr. Kitzler actively contributes to genetic characterization of nephrotic syndromes and polycystic kidney diseases , with a focus on precision medicine approaches for kidney transplant recipients and circulating podocyte-toxic factors in recurrent glomerular diseases. His work demonstrates interdisciplinary integration of clinical, genomic, and functional validation methods.
